BTG announced promising data on Sunday, 27 September, for DC BeadM1, supporting the efficacy and tolerability of doxorubicin-eluting DC BeadM1in the treatment of patients diagnosed with liver-confined hepatocellular carcinoma (HCC). The preliminary results of the single-centre, retrospective, single-arm study, in which patients achieved a median overall survival of 41 months, were presented during the 2015 CIRSE (Cardiovascular and Interventional Radiological Society of Europe) conference in Lisbon, Portugal. While DC Bead drug-eluting bead is backed by clinical safety and efficacy data in over 3,000 HCC patients, DC BeadM1 is a more recent addition to the product range. Designed with a narrow size distribution, so that it can travel deeper into the vasculature of the tumour, while also allowing for a more concentrated drug delivery, DC BeadM1 offers a new standard-of-care and a much more targeted therapy than conventional chemoembolisation for the treatment of HCC.
“Unlike the majority of cancer-types, for which improvements in diagnosis and treatment are set to result in a significant 17% reduction in mortality by 2030, the burden of HCC is continuing to grow, with mortality predicted to increase by 39% over this same time period,” said Camillo Aliberti from the Istituto Oncologico Veneto, Padua, Italy and lead author of the study. “We are always looking for refinements and improvements to the tools we have to optimise outcomes in this challenging patient population. DC BeadM1 is a promising new addition to the proven DC Bead product range and this study is significant in terms of the impressive safety and efficacy results it demonstrates.”
The study reviewed the treatment of 547 HCC patients treated with DC BeadM1 loaded with doxorubicin, between 2013 and 2015. Response, measured using mRECIST (modified Response Evaluation Criteria in Solid Tumors [RECIST] guideline), showed a median overall survival of 41 months, and a median progression-free survivalof 15 months. Furthermore, there were no significant treatment-related adverse events.
An economic evaluation of glass yttrium-90 microspheres versus sorafenib second piece of analysis, also presented during CIRSE 2015, looked to evaluate the cost-effectiveness of 90Y microspheres (TheraSphere), a novel radioembolization therapy that consists of millions of small glass microspheres containing radioactive 90Y, vs. sorafenib for the treatment of advanced HCC.
The analysis was conducted using the methodological criteria published by NICE. Within the analysis 10-year (lifetime) outcomes were estimated with results showing improvements across all measures for TheraSphere (Time-To-Progression (TTP) versus sorafenib [6.2 vs. 4.9 months], increased median Overall Survival (mOS) versus sorafenib [13.8 vs. 9.7 months], and increased quality-adjusted life years (QALYs) versus sorafenib [1.12 vs. 0.85 years]). As a result, the total lifetime cost of TheraSphere treatment (in the UK) was calculated to be significantly lower compared to sorafenib (£21,441 vs. £34,050).